Kummar, Shivaani
Lassen, Ulrik N.
Funding for this research was provided by:
LOXO Oncology
Bayer Corporation
Article History
First Online: 2 October 2018
Compliance with Ethical Standards
:
: Medical writing services were provided by Jim Heighway PhD of Cancer Communications and Consultancy Ltd. (Knutsford, UK) and were funded by Loxo Oncology, Inc. and Bayer. Open access publication of this article was funded by LOXO Oncology.
: Dr. Shivaani Kummar has received research funding for the clinical trial of larotrectinib. Dr. Ulrik Lassen declares that he has no conflicts of interest that might be relevant to the contents of this manuscript.